Putting the genie back in the bottle? Availability and presentation of oral artemisinin compounds at retail pharmacies in urban Dar-es-Salaam
-
* Corresponding author: S Patrick Kachur skachur@cdc.gov
Malaria Journal 2006, 5:25 doi:10.1186/1475-2875-5-25
Accesses
- Last 30 days: 80 accesses
- Last year: 785 accesses
- All time: 4186 accesses
Cited by
BioMed Central: 8 citations
|
Research
Prescription practices and availability of artemisinin monotherapy in India: where do we stand? Neelima Mishra, Anupkumar R Anvikar, Naman K Shah, Vineet Kumar Kamal, Surya Kant Sharma, Harish Chandra Srivastava, Manoj Kumar Das, Khageswar Pradhan, Hemant Kumar, Yogendra K Gupta, Pooja Gupta, Aditya Prasad Dash, Neena Valecha Malaria Journal 2011, 10:360 (13 December 2011) This paper reports the findings for a study carried out in India in 2008 which aimed to document the availability of and prescription practices with regards anti-malarial drugs and in particular artemisinin monotherapy. This is an important topic given India¿s geographically strategic location, lying between the epicentre of artemisinin resistance on the Thai-Cambodia border to the East ¿ and the continent of Africa to the West. The key finding are very concerning and it is reassuring that some action has apparently taken place since the study took place.
|
|
Research
Kathryn A O'Connell, Hellen Gatakaa, Stephen Poyer, Julius Njogu, Illah Evance, Erik Munroe, Tsione Solomon, Catherine Goodman, Kara Hanson, Cyprien Zinsou, Louis Akulayi, Jacky Raharinjatovo, Ekundayo Arogundade, Peter Buyungo, Felton Mpasela, Chérifatou Adjibabi, Jean Agbango, Benjamin Ramarosandratana, Babajide Coker, Denis Rubahika, Busiku Hamainza, Steven Chapman, Tanya Shewchuk, Desmond Chavasse Malaria Journal 2011, 10:326 (31 October 2011) This article is part of a collection on The ACTwatch project:... Useful synthesis of survey results providing essential information on the availability of anti-malarials, especially in the private sector where data has been extremely limited.
|
|
Research
Ahmed A Adedeji, Bilqees Sanusi, Azeez Tella, Motunrayo Akinsanya, Olubusola Ojo, Mufliat O Akinwunmi, Olubukola A Tikare, Isiaka A Ogunwande, Omobola A Ogundahunsi, Olajide O Ayilara, Taofeeqah T Ademola, Fatai A Fehintola, Olumide AT Ogundahunsi Malaria Journal 2011, 10:230 (9 August 2011) Pharmacovigilance is an important but too frequently negelected aspect of drug assessment and patient care and this article is important in as far as the authors address this important issue.
|
|
Review
Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities Christopher JM Whitty, Clare Chandler, Evelyn Ansah, Toby Leslie, Sarah G Staedke Malaria Journal 2008, 7(Suppl 1):S7 (11 December 2008) |
|
Research article
Malaria treatment in the retail sector: Knowledge and practices of drug sellers in rural Tanzania Manuel W Hetzel, Angel Dillip, Christian Lengeler, Brigit Obrist, June J Msechu, Ahmed M Makemba, Christopher Mshana, Alexander Schulze, Hassan Mshinda BMC Public Health 2008, 8:157 (9 May 2008) |
|
Research
Timothy O Abuya, Wilfred Mutemi, Baya Karisa, Sam A Ochola, Greg Fegan, Vicki Marsh Malaria Journal 2007, 6:57 (10 May 2007) Important contribution to the international debate over the value of retail drug providers as a delivery point for malaria treatment including recently adopted artemisinin-containing antimalarial combination treatments
|
|
Research
Molecular monitoring of Plasmodium falciparum resistance to artemisinin in Tanzania Kefas Mugittu, Blaise Genton, Hassan Mshinda, Hans Beck Malaria Journal 2006, 5:126 (19 December 2006) The study confirms the absence of PfATPase6 mutations in 615 asymptomatic P. falciparum infections in Tanzania. Resistance to artemisinin has not yet been selected in Tanzania, supporting the decision to adopt artemether+lumefantrine as first-line malaria treatment.
|
|
Research
Manuel W Hetzel, June J Msechu, Catherine Goodman, Christian Lengeler, Brigit Obrist, S Patrick Kachur, Ahmed Makemba, Rose Nathan, Alexander Schulze, Hassan Mshinda Malaria Journal 2006, 5:109 (14 November 2006) The decline in access may disproportionately affect the poorest and most remote groups. In view of the imminent policy change to artemisinin-based combination therapy, these issues need to be addressed urgently if the benefits of this new class of antimalarials are to be extended to the whole population
|